A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 22 Jul 2019
Price : $35 *
At a glance
- Drugs Oprozomib (Primary) ; Midazolam
- Indications Haematological malignancies; Multiple myeloma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Amgen
- 18 Jul 2019 Status changed from active, no longer recruiting to completed.
- 02 Jul 2019 Planned End Date changed from 12 Jun 2019 to 10 Jul 2019.
- 14 Mar 2019 Planned End Date changed from 30 Jun 2019 to 12 Jun 2019.